Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store.Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
PRESTO-3 Study Overview: Treatment Preferences for the Management of NETs
Acromegaly / Neuroendocrine Tumours (NETs)
File
3 pages
The PRESTO-3 study found a significant preference for the Lanreotide Ipsen syringe among nurses managing neuroendocrine tumours (NETs) and acromegaly. Discover the features that make this syringe a preferred choice, including its convenient format and ease of use. For a detailed overview, explore the pdf summary.
LAN-UK-000576 | February 2025
